Skip to main content
Top
Published in: Rheumatology International 3/2014

01-03-2014 | Short Communication

Autophagy is a key feature in the pathogenesis of systemic sclerosis

Authors: Tracy Frech, Ivana De Domenico, Maureen A. Murtaugh, Monica P. Revelo, Dean Y. Li, Allen D. Sawitzke, Stavros Drakos

Published in: Rheumatology International | Issue 3/2014

Login to get access

Abstract

Autophagosomes are formed during autophagy, which is activated by hypoxia and starvation. Autophagy is important for mast cell degranulation. We hypothesized that autophagy is a key feature in the pathogenesis of systemic sclerosis (SSc). We examined SSc clinical features and mast cell density across the presence and severity of autophagy. Skin punch biopsy was performed on 33 SSc patients and 6 healthy controls (HC). Autophagy was evaluated by immunofluorescence on paraffin sections using LC3-FITC staining on these patients. The intensity of staining and mast cell density was examined across clinical features in 19 of the SSc patients. Presence of autophagosome formation was assessed by EM in 17 of the SSc patients and 4 HC. In our SSc study population, 29 of subjects were female and 23 were limited cutaneous. Twenty-nine of 33 SSc patients had autophagy by LC3-FITC staining. Intensity of staining decreased with longer duration of SSc (p = 0.09) and RP (p = 0.10). Bloating and distention differed across level of intensity staining (Wilcoxon signed-rank test, p = 0.05), with the greatest levels among those with moderate intensity. On EM, autophagosome formation was present in 16 of 17 SSc patients and no HC. All SSc patients had perivascular mast cells. Autophagy was present in 29 of 33 SSc patients, and none of our HC suggesting importance in pathogenesis. Autophagy staining was greater among those with shorter duration of SSc. Bloating and distention were higher in patients with moderate autophagy staining. Perivascular mast cells were present in all SSc patients. The role of autophagy in vasculopathy and mast cell activation in SSc warrants further studies.
Literature
1.
go back to reference Frech T, Khanna D, Markewitz B, Mineau G, Pimentel R, Sawitzke A (2010) Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study. Arthr Rheum 62:2109–2116 Frech T, Khanna D, Markewitz B, Mineau G, Pimentel R, Sawitzke A (2010) Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study. Arthr Rheum 62:2109–2116
2.
go back to reference Martin JE, Broen JC, Carmona FD et al (2012) Identification of CSK as a systemic sclerosis genetic risk factor through genome wide association study follow-up. Hum Mol Genet 21:2825–2835PubMedCrossRef Martin JE, Broen JC, Carmona FD et al (2012) Identification of CSK as a systemic sclerosis genetic risk factor through genome wide association study follow-up. Hum Mol Genet 21:2825–2835PubMedCrossRef
3.
go back to reference Sargent JL, Whitfield ML (2011) Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Rev Clin Immunol 7:463–473PubMedCentralPubMedCrossRef Sargent JL, Whitfield ML (2011) Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Rev Clin Immunol 7:463–473PubMedCentralPubMedCrossRef
4.
go back to reference Gyger G, Baron M (2012) Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 14:22–29PubMedCrossRef Gyger G, Baron M (2012) Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep 14:22–29PubMedCrossRef
5.
go back to reference Razykov I, Thombs BD, Hudson M, Bassel M, Baron M (2009) Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthr Rheum 61:1765–1770CrossRef Razykov I, Thombs BD, Hudson M, Bassel M, Baron M (2009) Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthr Rheum 61:1765–1770CrossRef
6.
go back to reference Matucci-Cerinic M, Czirjak L (2009) Immune-endothelial-nerve interaction: an explanation for the failure of the gastrointestinal system in systemic sclerosis? Ann Rheum Dis 68:609–610PubMedCrossRef Matucci-Cerinic M, Czirjak L (2009) Immune-endothelial-nerve interaction: an explanation for the failure of the gastrointestinal system in systemic sclerosis? Ann Rheum Dis 68:609–610PubMedCrossRef
7.
go back to reference Murtaugh MA, Frech TM (2013) Nutritional status and gastrointestinal symptoms in systemic sclerosis patients. Clin Nutr 32(1):130–135 Murtaugh MA, Frech TM (2013) Nutritional status and gastrointestinal symptoms in systemic sclerosis patients. Clin Nutr 32(1):130–135
8.
9.
go back to reference Frieri M (1992) Systemic sclerosis. The role of the mast cell and cytokines. Ann Allergy 69:385–392, 95–96 Frieri M (1992) Systemic sclerosis. The role of the mast cell and cytokines. Ann Allergy 69:385–392, 95–96
10.
go back to reference Hawkins RA, Claman HN, Clark RA, Steigerwald JC (1985) Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 102:182–186PubMedCrossRef Hawkins RA, Claman HN, Clark RA, Steigerwald JC (1985) Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med 102:182–186PubMedCrossRef
11.
go back to reference Claman HN (1989) Mast cell changes in a case of rapidly progressive scleroderma-ultrastructural analysis. J Invest Dermatol 92:290–295PubMedCrossRef Claman HN (1989) Mast cell changes in a case of rapidly progressive scleroderma-ultrastructural analysis. J Invest Dermatol 92:290–295PubMedCrossRef
12.
go back to reference Sigal LH (2011) Basic science for the clinician 52: adipokines. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 17:157–161 Sigal LH (2011) Basic science for the clinician 52: adipokines. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 17:157–161
15.
go back to reference Cuervo AM, Bergamini E, Brunk UT, Droge W, Ffrench M, Terman A (2005) Autophagy and aging: the importance of maintaining “clean” cells. Autophagy 1:131–140PubMedCrossRef Cuervo AM, Bergamini E, Brunk UT, Droge W, Ffrench M, Terman A (2005) Autophagy and aging: the importance of maintaining “clean” cells. Autophagy 1:131–140PubMedCrossRef
16.
go back to reference Ushio H, Ueno T, Kojima Y et al (2011) Crucial role for autophagy in degranulation of mast cells. J Allergy Clin Immunol 127(1267–76):e6PubMed Ushio H, Ueno T, Kojima Y et al (2011) Crucial role for autophagy in degranulation of mast cells. J Allergy Clin Immunol 127(1267–76):e6PubMed
17.
go back to reference Del Principe D, Vona R, Giordani L, Straface E, Giammarioli AM (2011) Defective autophagy in fibroblasts may contribute to fibrogenesis in autoimmune processes. Curr Pharm Des 17:3878–3887PubMedCrossRef Del Principe D, Vona R, Giordani L, Straface E, Giammarioli AM (2011) Defective autophagy in fibroblasts may contribute to fibrogenesis in autoimmune processes. Curr Pharm Des 17:3878–3887PubMedCrossRef
18.
go back to reference Castello-Cros R, Whitaker-Menezes D, Molchansky A et al (2011) Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell Cycle 10:2140–2150PubMedCrossRef Castello-Cros R, Whitaker-Menezes D, Molchansky A et al (2011) Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell Cycle 10:2140–2150PubMedCrossRef
19.
go back to reference (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthr Rheum 23:581–90 (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthr Rheum 23:581–90
20.
go back to reference Rubinsztein DC, DiFiglia M, Heintz N et al (2005) Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1:11–22PubMedCrossRef Rubinsztein DC, DiFiglia M, Heintz N et al (2005) Autophagy and its possible roles in nervous system diseases, damage and repair. Autophagy 1:11–22PubMedCrossRef
21.
go back to reference Debnath J, Baehrecke EH, Kroemer G (2005) Does autophagy contribute to cell death? Autophagy 1:66–74PubMedCrossRef Debnath J, Baehrecke EH, Kroemer G (2005) Does autophagy contribute to cell death? Autophagy 1:66–74PubMedCrossRef
22.
go back to reference Weiner LM, Lotze MT (2012) Tumor-cell death, autophagy, and immunity. New Engl J Med 366:1156–1158PubMedCrossRef Weiner LM, Lotze MT (2012) Tumor-cell death, autophagy, and immunity. New Engl J Med 366:1156–1158PubMedCrossRef
Metadata
Title
Autophagy is a key feature in the pathogenesis of systemic sclerosis
Authors
Tracy Frech
Ivana De Domenico
Maureen A. Murtaugh
Monica P. Revelo
Dean Y. Li
Allen D. Sawitzke
Stavros Drakos
Publication date
01-03-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2827-8

Other articles of this Issue 3/2014

Rheumatology International 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine